Free Trial

Protagonist Therapeutics (PTGX) Earnings Date, Estimates & Call Transcripts

Protagonist Therapeutics logo
$40.69 -0.77 (-1.86%)
(As of 12/17/2024 ET)
Get Protagonist Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Protagonist Therapeutics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

PTGX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

PTGX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Protagonist Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241$3.75$3.75$3.75
Q2 20241-$0.64-$0.64-$0.64
Q3 20242-$0.64-$0.53-$0.59
Q4 20242-$0.55-$0.41-$0.48
FY 20246$1.92$2.17$2.05
Q1 20252-$0.61$1.92$0.66
Q2 20252-$0.63-$0.11-$0.37
Q3 20252-$0.65-$0.53-$0.59
Q4 20252-$0.67$0.87$0.10
FY 20258($2.56)$2.15($0.21)

Protagonist Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
8/6/2024--$0.50-$0.50--$0.50$40.00M$4.17M
5/7/2024Q1 2024$2.51$3.26+$0.75$3.26$300.00M$254.95M
2/27/2024Q4 2023$0.05$0.44+$0.39$0.44$60.00M$60.00M
11/2/2023Q3 2023-$0.68-$0.58+$0.10-$0.58--
8/3/2023Q2 2023-$0.65-$0.68 -$0.03-$0.68--
5/4/2023Q1 2023-$0.69-$0.67+$0.02-$0.67--
3/15/2023Q4 2022-$0.67-$0.69 -$0.02-$0.69--

Protagonist Therapeutics Earnings - Frequently Asked Questions

Protagonist Therapeutics (NASDAQ:PTGX) has a recorded annual revenue of $323.80 million.

Protagonist Therapeutics (NASDAQ:PTGX) has a recorded net income of -$78.96 million. PTGX has generated $2.66 earnings per share over the last four quarters.

Protagonist Therapeutics (NASDAQ:PTGX) has a trailing price-to-earnings ratio of 15.30 and a forward price-to-earnings ratio of 17.85.

Protagonist Therapeutics's earnings are expected to decrease from $2.28 per share to ($1.38) per share in the next year.

More Earnings Resources from MarketBeat



This page (NASDAQ:PTGX) was last updated on 12/18/2024 by MarketBeat.com Staff
From Our Partners